Vitamin E, Atherosclerosis and Thrombosis

Francesco Violi; Fausta Micheletta; Luigi Iuliano

doi:10.1055/s-0037-1615715

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2001; 85(05): 766-770
DOI: 10.1055/s-0037-1615715

Review Article

Schattauer GmbH

Vitamin E, Atherosclerosis and Thrombosis

Francesco Violi

¹Institute of Clinical Medicine I, University La Sapienza, Rome, Italy

,

Fausta Micheletta

¹Institute of Clinical Medicine I, University La Sapienza, Rome, Italy

,

Luigi Iuliano

¹Institute of Clinical Medicine I, University La Sapienza, Rome, Italy

› Institutsangaben

Abstract

Summary

Vitamin E, a major lipid-soluble, chain-breaking antioxidant includes several tocopherols having the biological activity of RRR-alpha-tocopherol. Vitamin E circulates in the blood as free tocopherol bound to beta-lipoproteins and is present in cell membrane where it exerts a potent defence against lipid peroxidation (1). Blood concentration of vitamin E in humans ranges from 25 to 30 μM, depending on daily intake and body’s ability to absorb fat (1). In the last decade the scientific interest on biological activity of vitamin E increased because of a growing body of evidence linking this vitamin with atherosclerosis and its complications (2). Thus, the oxidative hypothesis of atherosclerosis suggests that LDL accumulates within vessel wall, in particular in the macrophages, as a consequence of its oxidative modification mediated by resident cells (3, 4). A reduced defence against LDL oxidation could favour this process and accelerate atherosclerotic progression. Accordingly, patients with coronary heart disease have lower plasma concentration of vitamin E than controls (2) and prospective studies demonstrated that a daily assumption of vitamin E reduces cardiovascular events (5). According to the oxidative hypothesis of atherosclerosis, this effect has been attributed to the inhibition of LDL oxidation. Alternative mechanism potentially implicated in the antiatherosclerotic activity of vitamin E includes its interference with the activity of platelet and monocyte, in which the intracellular redox status plays an important functional role (6, 7). As platelets and monocytes are both involved in the pathophysiologic process leading to atherosclerotic lesion, the interference of vitamin E with the biological function of these cells may represent another important tool to explore the anti-atherosclerotic activity of vitamin E. This review will focus on the open issues related to the use of vitamin E in clinical studies and the potential usefulness in investigating platelet function and clotting activation in patients treated with vitamin E.

Volltext

Referenzen

References
1 Machlin LJ. Vitamin E. In: Machlin LJ. ed. Handbook of Vitamins: Nutritional, Biochemical and Clinical Aspects. New York, N. Y.: Marcel Dekker, Inc.; 1984. pp 99-145.
2 Riemersma RA, Word DA, Macintyre CCA, Elton RA, Oliver MF. Risk of angina pectoris and plasma concentration of vitamins A, C and E and carotene. Lancet 1991; 337: 1-5.
3 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989; 320: 915-24.
4 Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272: 20963-6.
5 Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-16.
6 Iuliano L, Colavita AR, Leo R, Pratico D, Violi F. Oxygen free radicals and platelet activation. Free Radic Biol Med 1997; 22: 999-1006.
7 Crutchley DJ, Que BG. Copper-induced Tissue Factor expression in human monocytic TPH-1 cells and its inhibition by antioxidants. Circulation 1995; 92: 238-43.
8 Iuliano L, Pedersen JZ, Rotilio G, Ferro D, Violi F. A potent chain breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med 1995; 18: 239-47.
9 Iuliano L, Pedersen JZ, Camastra C, Bello V, Ceccarelli S, Violi F. Protection of low density lipoprotein oxidation by the antioxidant agent IRFI005, a new synthetic hydrophilic vitamin E analogue. Free Radic Biol Med 1999; 26: 858-68.
10 Gutteridge JMC, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 1990; 15: 129-35.
11 Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13: 341-90.
12 Morel DW, Hessler JR, Chisholm GM. Low dwnsity lipoprotein cytotoxi-city induced by free radical peroxidation of lipid. J Lipid Res 1983; 24: 1070-6.
13 Iuliano L, Colavita AR, Leo R, Pratico D, Violi F. Oxygen free radicals and platelet activation. Free Radic Biol Med 1997; 22: 999-1006.
14 Praticò D. F2-isoprostanes: a sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147: 1-10.
15 Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
16 Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994; 14: 605-16.
17 Pratico D, Iuliano L, Mauriello A, Spagnoli L, Lawson JA, Rokach J, Maclouf J, Violi F, FitzGeral GA. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 1028-34.
18 Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum J, Palinski W, Shah PK, Cercek B, Nilsson Rengstrom J. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol 1998; 18: 884-93.
19 Freyschuss A, Stiko-rahm A, Swedenborg Henriksson P, Bjorkem I, Berglund L, Nilsson J. Antioxidants treatment inhibits the development of intimal tickening after balloon injury of the aorta in hypercholesterolemic rabbit. J Clin Invest 1993; 91: 1282-88.
20 Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, Chao Y. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholestrol-fed rabbits by the antioxidant N,N’-diphenyl-phenylendiemanine. J Clin Invest 1992; 89: 1885-91.
21 Sharma N, Desigan B, Ghosh S, Sanyas SN, Ganguly NK, Majumdar S. Effect of Antioxidant vitamin E as a protective factor in experimental atherosclerosis in rhesus monkeys. Ann Nutr Metab 1999; 43: 181-90.
22 Praticò D, Tangirala RK, Rader DJ, Rokach J, FitzGerald GA. Vitamin E suprresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 1998; 4: 1189-92.
23 Iuliano L, Mauriello A, Sbarigia E, Spagnoli LG, Violi F. Radiolabeled native low-density lipoproteins injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque. Effect of Vitamin E supplementation. Circulation 2000; 101: 1249-1254.
24 Tribble DL. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and β-carotene. Circulation 1999; 99: 591-5.
25 Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, taylor PR, Heinonen OP. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349: 1715-20.
26 Stephens NG, Parsons A, Schofield PM, Kelly F, Cheesman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996; 347: 781-6.
27 Dietary supplementation with n-3 plyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999; 354: 447-55.
28 The Heart Outcomes prevention Evaluation study Investigator.. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 2000; 342: 154-60.
29 Burton GW, Traber MG, Acuff RV, Walters DN, Kayden H, Hughes L, Ingold KU. Human plasma and tissue alpha-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E. Am J Clin Nutr 1998; 67: 669-84.
30 Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-72.
31 Diaz MN, Frei B, Vita JA, Keaney jr. JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-16.
32 Micheletta F, Iuliano L, Natoli S, Violi F. Bioavaibility of vitamin E in relation to food intake in humans. Haematologica 2000; 85 suppl 10 (abstract).
33 Adamstone FB. The effects of vitamin E deficiency on the development of chick. J Morphol Physiol 1931; 52: 47-89.
34 Mason KE. In Sebrell W, Harris R. S.. eds. The vitamins. Vol. III New York: Academic Press; 1954: 514-67.
35 Corrigan JJ. Activation of coagulation and disseminated intravascular coagulation in the newborn. Am J Pediatr Hematol Oncol 1979; 1: 245-9.
36 Jain SK, McCoy B, Wise R. Vitamin E and the hypercogulability of neonatal blood. Clin Chim Acta 1994; 225: 97-103.
37 Yoshikawa T, Furukawa Y, Murakami M, Watanabe K, Kondo M. The effect of vitamin E on endotoxin-induced disseminated intravascular coagulation in rats. Thromb Haemost 1982; 48: 235-7.
38 Rota S, McWilliam NA, Baglin TP, Byrne CD. Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood 1998; 91: 508-15.
39 Shibanuma M, Kuroki T, Nose K. Stimulation by hydrogen peroxide of DNA synthesis, competence family gene expression and phosphorylation of a specific protein in quiescent balb/3T3 cells. Oncogene 1990; 5: 1025-32.
40 Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NK-kappa B transcription factor and HIV-1. EMBO J 1991; 10: 2247-58.
41 Schreck R, Meier B, Manel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitor of nuclear factor kB activation in intact cells. J Exp Med 1992; 175: 1181-94.
42 Brisseau GF, Dackiw APB, Cheung PYC, Christie N, Rotstein OD. Posttranscriptional regulation of macrophages tissue factor expression by antioxidants. Blood 1995; 85: 1025-35.
43 Oeth P, Mackman N. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the Tissue Factor gene in human monocytic cells. Blood 1995; 86: 4144-52.
44 Ferro D, Basili S, Praticò D, Iuliano L, Fitzgerald GA, Violi F. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood 1999; 93: 2945-50.
45 Praticò D, Ferro D, Iuliano L, Rokach J, Conti F, Valesini G, FitzGerald GA, Violi F. Ongoing prothrombotic state in patients with antiphospolipid antibodies: a role for lipid peroxidation. Blood 1999; 93: 3401-7.
46 Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci USA 1995; 92: 8171-5.
47 Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol 1996; 77: 545-6.
48 Violi F, Ghiselli A, Iuliano L, Alessandri C, Cordova C, Balsano F. Influence of hydroxyl radical scavengers on platelet function. Haemostasis 1988; 18: 91-8.
49 Iuliano L, Praticò D, Ghiselli A, Bonavita MS, Violi F. Superoxide dismutase triggers activation of primed platelets. Arch Biochem Biophys 1991; 289: 180-3.
50 Iuliano L, Praticò D, Bonavita MS Violi.. Involvement of Phospholipase A₂ in H₂O₂-dependent platelet aggregation. Platelets 1992; 2: 87-90.
51 Iuliano L, Violi F, Pedersen JZ, Praticò D, Rotilio G. Free-radical-mediated platelet activation by hemoglobin released from red blood cells. Arch Biochem Biophys 1992; 289: 220-4.
52 Iuliano L, Pedersen JZ, Praticò D, Rotilio G, Violi F. Role of hydroxyl radicals in the activation of human platelets. Eur J. Biochem 1994; 221: 695-704.
53 Praticò D, Pasin M, Barry OP, Ghiselli A, Sabatino G, Iuliano L, FitzGerald GA, Violi F. Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. Circulation 1999; 99: 3118-24.
54 Steiner M, Anastasi J. Vitamin E: an inhibitor of the platelet release reaction. J Clin Invest 1976; 57: 732-7.
55 Freedman JE, Farhat JH, Loscalzo J, Keaney J. Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996; 94: 2434-40.
56 Pignatelli P, Pulcinelli F, Lenti L, Gazzaniga PP, Violi F. Vitamin E inhibits collagen-induced platelet activation by blunting hydrogen peroxide. Arterioscl Thromb Vasc Biol 1999; 19: 2542-7.
57 Pignatelli P, Pulcinelli F, Lenti L, Gazzaniga PP, Violi F. Hydrogen peroxide is involved in collagen-induced platelet activation. Blood 1998; 91: 484-90.
58 Calzada C, Bruckdorfer R, Rice-Evans CA. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 1997; 128: 97-105.
59 Davi G, Alessandrini P, Mezzetti A, Minotti G, Bucciarelli T, Costantini F, Cipollone F, Bittolo Bon G, Ciabattoni G, Patrono C. In vivo formation of 8-epi-prostaglandin F2alpha is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 3230-5.
60 Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin F2 and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-9.